LifeVantage Corporation (NasdaqCM:LFVN) in our automated value investing analysis, with the cash flow history and price comparison below.
Advertisement helps keep Trendshare free for most readers.
Estimate how long you need to hold LifeVantage Corporation to reach your target.
Based on historical returns, we believe that LifeVantage Corporation can grow its free cash at a rate of about 36%. That's positive!
| Advantages | Disadvantages |
|---|---|
|
|
| LFVN Price (LifeVantage Corporation stock price per share) |
$4.15 | |
|
|
LFVN Fair Price (based on intrinsic value) |
$2.65 |
| LFVN Safety Price (based on a variable margin of safety) | $1.59 | |
|
Try your own return
The fair price above uses a 10.1% discount rate, the long-run US stock return (10.1% geometric, 1926 to 2025, from Bessembinder's working paper, updated 2026-11-09), and 2.5% terminal growth. A higher rate suits a higher return target and gives a lower value. Value per share: |
||
| PE Ratio versus Sector | 2% lower than other Healthcare stocks | |
| PE Ratio versus Industry | 0% lower than other Drug Manufacturers - General stocks | |
| Free Cash Flow Jitter | 46% | |
| Dividend Yield | 3.89% (tax impact) | Shares Shorted | 906,622 |
In the six months to 2026-11-22, 1 insider bought in 2 trades, about $12 thousand, and 2 insiders sold in 3 trades, about $141 thousand.
The six months before that had 1 buy and 0 sales.
Net open-market activity was sales of about $129 thousand.
Open-market buys and sells reported by LifeVantage Corporation's officers, directors, and 10% owners on SEC Form 4. Routine transactions (tax withholding, option exercises, and stock grants) are excluded -- these are discretionary trades only.
| Date | Insider | Type | Shares | Price |
|---|---|---|---|---|
| 2026-09-15 | Lewis Darwin | Buy | 976 | $6.22 |
| 2026-09-14 | Cunningham Kristen (Chief Sales Officer) | Sell | 8,901 | $6.18 |
| 2026-09-11 | Cunningham Kristen (Chief Sales Officer) | Sell | 100 | $6.41 |
| 2026-06-15 | Lewis Darwin | Buy | 705 | $8.60 |
| 2026-06-03 | BEINDORFF MICHAEL A | Sell | 10,000 | $8.55 |
| 2026-03-16 | Lewis Darwin | Buy | 1,055 | $5.23 |
This stock has short interest! This means that people have shorted it.
Why does that matter? They've made a bet that price will decrease from where they bought it. Maybe there are financial problems, or maybe there's a value play.
As of the latest analysis, there are 906,622 shares shorted. With 9,296,322 shares available for purchase and an average trading volume over the past 10 trading days of 88,960, it would take at least 10.2 days for all of the short holders to cover their shorts.
What does this mean to you? At this volume, it'll take more than two trading weeks for shorts to cover. This may indicate a short squeeze play would work! If this stock has good fundamentals and it'll take a while for the short holders to cover, buying now could net you bigger short-term technical gains if and as the price rises.
Related guides: good annual rate of return · high-yield stocks · forecasting earnings growth
How to read this: free cash flow in plain terms, free cash flow jitter.
Each year names the SEC filer that reported it, so a change of filer shows up here.
| Fiscal year | SEC filer (CIK) | Free cash flow (USD millions) |
|---|---|---|
| 2011 | 849146 | 4.6 |
| 2012 | 849146 | 18.2 |
| 2013 | 849146 | 8.2 |
| 2014 | 849146 | 9.8 |
| 2015 | 849146 | 11.1 |
| 2016 | 849146 | 3.9 |
| 2017 | 849146 | 4.6 |
| 2018 | 849146 | 11.4 |
| 2019 | 849146 | 15.8 |
| 2020 | 849146 | 16 |
| 2021 | 849146 | 13.3 |
| 2022 | 849146 | 4.9 |
| 2023 | 849146 | 4.1 |
| 2024 | 849146 | 9.5 |
| 2025 | 849146 | 9.5 |
| 2026 | 849146 | 7.9 |
Download the yearly data as CSV.
How to read this: what free cash flow is, why earnings matter.
Over the 15 fiscal years from 2011 to 2026 with positive net income, operating cash flow totaled $183 million against net income of $107 million, or 1.70 times. Net income was negative in 1 of the 16 years, and those years are left out of the ratio.
In 2026, operating cash flow was 2.02 times net income, compared with 1.50 times for the earliest three years (2011 to 2013).
In 2026, capital expenditures were $3.6 million, 34.9% of operating cash flow of $10.2 million, which leaves an estimated $6.7 million after capex. Across the 16 years with reported capex, it averaged 20.0% of operating cash flow. This uses that year's own capital expenditures, not the five-year average behind the free cash flow table, so the two can differ.
| Fiscal year | Net income (USD millions) | Operating cash flow (USD millions) | Capital expenditures (USD millions) | Operating cash flow / net income |
|---|---|---|---|---|
| 2011 | -50.8 | 4.7 | 0.1 | n/a |
| 2012 | 12.5 | 19.4 | 2.2 | 1.55 |
| 2013 | 7.6 | 10.7 | 5.1 | 1.40 |
| 2014 | 11.4 | 12.1 | 1.9 | 1.06 |
| 2015 | 7.1 | 13.2 | 1.2 | 1.86 |
| 2016 | 6.1 | 6 | 0.6 | 0.99 |
| 2017 | 1.6 | 6.6 | 1.1 | 4.10 |
| 2018 | 5.8 | 13.3 | 4.6 | 2.30 |
| 2019 | 7.4 | 17.8 | 2.5 | 2.39 |
| 2020 | 11.5 | 18.3 | 2.7 | 1.59 |
| 2021 | 12.9 | 16.3 | 3.7 | 1.26 |
| 2022 | 3.1 | 8 | 1.5 | 2.55 |
| 2023 | 2.5 | 6.8 | 3.1 | 2.69 |
| 2024 | 2.9 | 12.2 | 2.2 | 4.15 |
| 2025 | 9.8 | 11.9 | 1.4 | 1.21 |
| 2026 | 5.1 | 10.2 | 3.6 | 2.02 |
How to read this: why companies buy back shares, dividend yield explained.
Over the 10 fiscal years from 2015 to 2026 with dividend or share repurchase facts, estimated free cash flow totaled $104 million. That estimate uses the average of up to five years of capital expenditures, not each year's own, so it is not a reported figure.
In the 5 of those years with dividend payment facts, dividends paid totaled $13.3 million, 37.0% of the estimated free cash flow of those years. Estimated free cash flow was at least the dividends paid in 5 of those 5 years.
In 10 of the 10 years, cash spent repurchasing shares was at least 5% of that year's estimated free cash flow, and in those years it totaled $54.6 million. Smaller amounts are left out of this sentence because they can be shares withheld to pay employees' taxes on stock awards.
In 2026, dividends and cash spent repurchasing shares together were $4.4 million, 55.6% of estimated free cash flow of $7.9 million.
| Fiscal year | Estimated free cash flow (USD millions) | Dividends paid (USD millions) | Cash spent repurchasing shares (USD millions) | Total returned (USD millions) | Total as a percent of estimated free cash flow |
|---|---|---|---|---|---|
| 2015 | 11.1 | n/a | 9.8 | 9.8 | 88.5% |
| 2018 | 11.4 | n/a | 1.5 | 1.5 | 13.2% |
| 2019 | 15.8 | n/a | 4.7 | 4.7 | 29.5% |
| 2020 | 16 | n/a | 5.4 | 5.4 | 33.7% |
| 2021 | 13.3 | n/a | 11.9 | 11.9 | 89.4% |
| 2022 | 4.9 | 0.4 | 8.8 | 9.2 | 186.5% |
| 2023 | 4.1 | 1.6 | 0.8 | 2.4 | 58.4% |
| 2024 | 9.5 | 6.9 | 6.4 | 13.4 | 140.1% |
| 2025 | 9.5 | 2.1 | 3.1 | 5.2 | 55.0% |
| 2026 | 7.9 | 2.3 | 2 | 4.4 | 55.6% |
Free cash flow here is an estimate: operating cash flow less the average of up to five years of capital expenditures. Cash spent repurchasing shares can include shares withheld to pay employees' taxes on stock awards. The entry n/a means the filings gave no usable figure, not that the amount was zero. Source: the company's annual reports to the SEC.
How to read this: earnings and margins.
Revenue was $38.9 million in 2011 and $183 million in 2026, a compound annual growth rate of 10.9% over 15 years.
Revenue fell 20.1% from 2025 to 2026.
Our estimated free cash flow was $7.9 million in 2026, 4.3% of revenue. In 2011 the estimated margin was 11.7%. This estimate charges each year with the average of up to five years of capital expenditures, so it is not the free cash flow the company reported.
| Fiscal year | Revenue (USD millions) | Estimated free cash flow (USD millions) | Estimated free cash flow / revenue |
|---|---|---|---|
| 2011 | 38.9 | 4.6 | 11.7% |
| 2012 | 126 | 18.2 | 14.4% |
| 2013 | 208 | 8.2 | 3.9% |
| 2014 | 214 | 9.8 | 4.6% |
| 2015 | 190 | 11.1 | 5.8% |
| 2016 | 207 | 3.9 | 1.9% |
| 2017 | 199 | 4.6 | 2.3% |
| 2018 | 203 | 11.4 | 5.6% |
| 2019 | 226 | 15.8 | 7.0% |
| 2020 | 233 | 16 | 6.9% |
| 2021 | 220 | 13.3 | 6.1% |
| 2022 | 206 | 4.9 | 2.4% |
| 2023 | 213 | 4.1 | 1.9% |
| 2024 | 200 | 9.5 | 4.8% |
| 2025 | 229 | 9.5 | 4.2% |
| 2026 | 183 | 7.9 | 4.3% |
How to read this: how debt and assets are compared, the current ratio.
In 2026, cash and equivalents were $14.9 million against total liabilities of $28.5 million, or 52.3% of total liabilities. Total liabilities include everything the company owes, not only borrowed money.
Total liabilities were 45.9% of total assets in 2026, compared with 266.5% in 2011, a decrease of 220.6 percentage points.
Stockholders equity was $33.6 million in 2026, up from negative equity of -$20.8 million in 2011.
Based on our estimated free cash flow, cash flow return on invested capital (CROIC) was 29.2% in 2026. Invested capital here is total assets less cash and current liabilities.
| Fiscal year | Total assets (USD millions) | Cash and equivalents (USD millions) | Total liabilities (USD millions) | Stockholders equity (USD millions) |
|---|---|---|---|---|
| 2011 | 12.5 | 6.4 | 33.3 | -20.8 |
| 2012 | 44.5 | 24.6 | 16.2 | 28.3 |
| 2013 | 55.5 | 26.3 | 21.5 | 33.9 |
| 2014 | 54 | 20.4 | 51.7 | 2.3 |
| 2015 | 39.8 | 13.9 | 38 | 1.8 |
| 2016 | 50.9 | 7.9 | 40.2 | 10.6 |
| 2017 | 45.2 | 11.5 | 30.7 | 14.5 |
| 2018 | 51.1 | 16.7 | 29.2 | 21.9 |
| 2019 | 55.3 | 18.8 | 28.1 | 27.2 |
| 2020 | 58.9 | 22.1 | 25.6 | 33.3 |
| 2021 | 78.7 | 23.2 | 41.9 | 36.8 |
| 2022 | 70.7 | 20.2 | 39.2 | 31.5 |
| 2023 | 66.1 | 21.6 | 31.5 | 34.6 |
| 2024 | 60.3 | 16.9 | 34.3 | 26 |
| 2025 | 72 | 20.2 | 37.3 | 34.6 |
| 2026 | 62.1 | 14.9 | 28.5 | 33.6 |
Free cash flow was positive in all 16 fiscal years we have for LifeVantage Corporation under its current SEC filer.
LifeVantage Corporation is priced at $4.15, above our fair value estimate of $2.65 and its safe value of $1.59.
Average free cash flow over the last three years of data was $9 million, and across the first three years it was $10.3 million; over the period it fell.
Free cash flow is volatile from year to year, with a variability measure of 46%.
LifeVantage Corporation yields 3.89% in dividends.
These figures are automated calculations from SEC filings and the recent price. They are not a recommendation to buy or sell. See how we estimate value.
How to read this: the price to earnings ratio.
Its trailing P/E ratio is 2% below the average for stocks in the Healthcare sector.
Its trailing P/E ratio is in line with the average for stocks in the Drug Manufacturers - General industry.
A P/E ratio depends on trailing earnings, which one-time items can distort, so a lower P/E is not by itself evidence of value.
These are companies in the Drug Manufacturers - General industry, the ones closest in market capitalization to LifeVantage Corporation, limited to companies whose pages we publish. The figures come from our latest data for each company.
| Company | Market cap (USD millions) | P/E | Dividend yield | Cash yield | Price versus our estimate |
|---|---|---|---|---|---|
| LifeVantage Corporation (LFVN) | 52.6 | 19.8 | 3.9% | - | 57% above |
| SIGA Technologies (SIGA) | 172 | 240.0 | - | 8.2% | 87% below |
| Collegium Pharmaceutical (COLL) | 768 | 22.7 | - | - | 155% above |
| Amphastar Pharmaceuticals (AMPH) | 1,205 | 13.0 | - | 0.9% | 98% above |
| Innoviva (INVA) | 1,309 | 7.8 | - | - | 12% above |
| Phibro Animal Health Corporation (PAHC) | 1,352 | 13.9 | 1.4% | - | 82% above |
| ANI Pharmaceuticals (ANIP) | 1,558 | 13.9 | - | - | 188% above |
Industry labels are approximate, and companies in one industry can run quite different businesses, so a peer may not be a close match.
Ratios on different fiscal calendars are not strictly comparable, and a trailing P/E can be distorted by one-time items.
Every fiscal year on this page is reported by one SEC filer, CIK 849146.
Each figure on this page comes from that filer.
How to read this: understanding investment risk.
Company figures come from the annual reports (Form 10-K) that each company files with the SEC, read from the SEC EDGAR company facts data. The share price and other market data come from a market data provider.
Free cash flow here is operating cash flow minus capital spending. To keep one unusual year from swinging the result, each year is charged with the average of up to five years of capital spending, so the figure is an estimate and not the free cash flow a company reports.
The fair price is the present value of ten years of projected free cash flow plus a terminal value, discounted at 10.1 percent a year, the long-run return of US stocks, with 2.5 percent growth after year ten. The figures on this page are estimates, not advice.
This analysis covers US companies that file 10-K annual reports. Free cash flow describes banks, real estate investment trusts and funds poorly, so treat their figures with extra caution. In the cash returned and balance sheet tables, a value of zero is treated as a gap in the data, not as a real zero.
Read the filings yourself: LFVN annual reports (10-K) on SEC EDGAR. To try your own growth rate, use the intrinsic value calculator on this page. Our editorial standards explain how Trendshare handles its sources and corrections.
Advertisement supports free stock analysis content.
Does LifeVantage Corporation have a coherent story? Does it have a plan to continue to make money? Is it worth your time? Only you can decide where to go from here. Our investment guide helps you ask the right questions, including how to buy stocks. Use these research links for more information.
This example shows how we apply the Trendshare checklist to LFVN: earnings power, cash generation, valuation, and margin of safety.
We check: business quality, free cash flow, P/E, and margin of safety.
Most Popular Articles
What is the Difference Between Trading Stocks and Investing?
Why Do Companies Perform Stock Buybacks?
How Does Portfolio Churning Affect Your Returns?
How Do Tariffs Affect the Stock Market?
DCA vs Lump Sum: 155 Years of S&P 500 Historical Data
How to Invest $1000 in the Stock Market